LIPO | Lipella Pharmaceuticals Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.3600 - 2.5102
52 Week Range	2.2100 - 12.00
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	44,655
Average Volume	168,968
Shares Outstanding	1,208,955
Market Cap	2,913,582
Sector	Healthcare
Industry	Biotechnology
IPO Date	2022-12-19

Valuation
Profitability
Growth
Health
P/E Ratio	-0.56
Forward P/E Ratio	N/A
EPS	-4.29
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	5
Country	USA
Website	LIPO

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.

LIPO's peers: CYCN, ICCC, SNTI, FENC, MNPR, AMTI, AKESF, ADYX, ASCLF, EPRXF, AVXT, TRGNF, ACOGF, ANEB, NGENF, ACRV, PTIX, MIRO, ELYM, INBX, MACK, CELC, ELVN

*Chart delayed

Analyzing fundamentals for LIPO we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see LIPO Fundamentals page.

Watching at LIPO technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on LIPO Technicals page.